The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC).
Natacha Chaumard-Billotey
Other Remuneration - PharmaMar; Roche
Sylvie Chabaud
No relevant relationships to disclose
Helen Jane Boyle
Honoraria - Janssen-Cilag; Novartis; Sanofi
Other Remuneration - Janssen-Cilag; Pfizer; Sanofi
Bertrand Favier
Honoraria - Roche
Other Remuneration - Pfizer; Roche
Yves Devaux
No relevant relationships to disclose
Jean-Pierre Droz
No relevant relationships to disclose
Aude Flechon
Honoraria - Janssen
Other Remuneration - Astellas Pharma; Sanofi